Search Results
Jun 11, 2025, 09:00 ET Netbr e iProov firmam parceria para elevar a segurança na identidade digital
como a LGPD, Open Finance, Open Insurance e demais padrões da indústria, permitindo integração ágil com plataformas de gestão de identidade e acesso (IGA/IAM). Isso fortalece a governança de identidade e oferece um ecossistema de autenticação seguro e escalável. Allan Mariani,
More news about: Netbr
Jun 11, 2025, 08:05 ET New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
skin clearance, greater proportions of TREMFYA®-treated patients (73% for Q4W and 68% for Q8W) achieved an Investigator's Global Assessment (IGA) score of 0/1d (clear or almost clear skin) at Week 24 versus 31% receiving placebo.1The data from the APEX study
More news about: Johnson & Johnson
Jun 09, 2025, 14:15 ET Calliditas Therapeutics Presented at the 62nd European Renal Association Congress
patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-Ag1), causing IgA nephropathy. About Primary Immunoglobulin A NephropathyPrimary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger's Disease) is a rare, progressive, chronic
More news about: Asahi Kasei Corporation
Jun 09, 2025, 02:02 ET Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association
with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and lupus nephritis (LN), offering treatment options for
More news about: Everest Medicines
Jun 06, 2025, 02:03 ET Omada führt KI-Assistenten für Identity Governance Administration ein
eine dialogorientierte und benutzerfreundliche Schnittstelle für die Bearbeitung wichtiger IGA-Aufgaben. Javi lässt sich nahtlos in gängige Kollaborationstools wie Microsoft Teams integrieren und vereinfacht die IGA-Verwaltung durch die Rationalisierung von Prozessen wie z. B.: Antrag
More news about: Omada
Jun 06, 2025, 02:03 ET Omada lanza el Asistente de IA para la Administración de Gobernanza de Identidad
tareas de IGA en herramientas de colaboración como Microsoft Teams. COPENHAGUE, Dinamarca, 6 de junio de 2025 /PRNewswire/ -- Omada A/S ("Omada"), un líder mundial en gobernanza y administración de identidad (IGA), anunció
More news about: Omada
Jun 06, 2025, 02:03 ET Omada dévoile Javi, son assistant IA pour transformer l'administration et la gouvernance des identités
instantané à leur solution IGA directement dans une interface avec laquelle ils travaillent tous les jours. Cela permettra aux utilisateurs de demander et d'approuver l'accès ou de prendre d'autres mesures à partir de n'importe quel appareil sans avoir à se connecter à la solution IGA. »
More news about: Omada
Jun 05, 2025, 22:10 ET 耐賦康®最新研究結果亮相第62屆歐洲腎臟協會大會：證實「盡早治療」可實現更顯著臨床獲益
[8]，具有良好的安全性。耐賦康®專為IgA腎病患者研製，每顆膠囊含布地奈德4mg，通過特殊的遲釋及緩釋雙重制劑工藝，將布地奈德靶向釋放於迴腸末端的黏膜B細胞（包括派爾集合淋巴結），膠囊溶解後，三層包衣微丸持續穩定釋放布地奈德，高濃度覆蓋整個靶區域，從而減少誘發IgA腎病的半乳糖缺陷的IgA1抗體（Gd-IgA1）產生，進而干預發病機制上游階段，達到治療IgA腎病的作用。 2019年6月，雲頂新耀與Calliditas Therapeutics 簽訂獨家授權許可協議，獲得在大中華地區和新加坡開發以及商業化耐賦康®的權利。該協議於2022年3月擴展，將韓國納入雲頂新耀的授權許可範圍。
More news about: 雲頂新耀
Jun 04, 2025, 18:01 ET Congreso ERA: eficacia y seguridad sostenidas de zigakibart en pacientes con nefropatía IgA
Prof. Barratt. El tratamiento también dio lugar a reducciones sostenidas de las inmunoglobulinas séricas, incluido un descenso del 74% de IgA y la Gd-IgA1 patogénica, en consonancia con la inhibición de la vía APRIL. Zigakibart fue bien tolerado en todo momento. La mayoría de los acontecimientos
More news about: ERA Congress
Jun 04, 2025, 18:01 ET 유럽 신장학회 연례 학술대회: 장기 데이터는 IgA 신증 환자에게서 지가키바트의 지속적인 유효성과 안전성 보여줘
여과율(Estimated glomerular filtration rate•eGFR)은 모든 하위 그룹에서 안정적으로 유지됐다. 배럿 교수는 "단백뇨 반응 그룹에서도 100주 동안 eGFR 안정화가 일관되게 유지됐다는 건 특히 고무적인 일"이라고 말했다. 치료는 IgA 및 병리적 Gd-IgA1을 74% 낮추는 등 혈청 면역글로불린(serum immunoglobulins) 수치의 지속적인 감소로 이어지며 APRIL 경로 억제 효과를 확인해줬다. 지가키바트는 전반적으로 우수한 내약성을 보여줬다. 대부분의 부작용은 경증 또는 중등도에
More news about: ERA Congress
Jun 04, 2025, 18:01 ET ERA大會：長期數據顯示Zigakibart於IgA腎病患者中持續展現療效及安全性
奧地利維也納2025年6月5日 /美通社/ -- 來自正在進行中的第一／二期研究的最新100週數據顯示，Zigakibart（研究中之抗APRIL單克隆抗體）進一步支持其作為 IgA 腎病（IgAN）潛在疾病修飾治療的可能性。今日於第62屆ERA大會發表的研究結果顯示，Zigakibart可持續達致蛋白尿緩解、維持穩定腎功能，並展現良好的安全性概況。 IgA腎病（IgAN）是全球最常見的腎小球疾病形式，亦是導致慢性腎病的常見原
More news about: ERA Congress
Jun 04, 2025, 18:01 ET ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with
More news about: ERA Congress
Jun 04, 2025, 18:01 ET ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with
More news about: ERA Congress
Jun 04, 2025, 18:01 ET ERA Congress: Langfristige Daten zeigen nachhaltige Wirksamkeit und Sicherheit von zigakibart bei Patienten mit IgA-Nephropathie
Barratt. Die Behandlung führte auch zu einer anhaltenden Senkung der Serumimmunoglobuline, einschließlich eines 74%igen Rückgangs von IgA und pathogenem Gd-IgA1, was mit der Hemmung des APRIL-Signalwegs übereinstimmt. Zigakibart wurde durchweg gut vertragen. Die meisten unerwünschten Ereignisse
More news about: ERA Congress
Jun 04, 2025, 18:01 ET Congresso ERA: Dados de longo prazo mostram eficácia e segurança sustentadas do zigakibart em pacientes com nefropatia por IgA
encorajadora", disse o Prof. Barratt. O tratamento também levou a reduções sustentadas nas imunoglobulinas séricas, incluindo uma queda de 74% na IgA e na Gd-IgA1 patogênica, consistente com a inibição da via APRIL. Zigakibart foi bem tolerado por toda parte. A maioria dos eventos adversos foi leve
More news about: ERA Congress
Jun 04, 2025, 18:01 ET Congrès de l'ERA : Les données à long terme montrent une efficacité et une sécurité durables de zigakibart chez les patients atteints de néphropathie à IgA
Prof. Barratt. Le traitement a également entraîné des réductions durables des immunoglobulines sériques, notamment une baisse de 74 % des IgA et des Gd-IgA1 pathogènes, ce qui est cohérent avec l'inhibition de la voie APRIL. Zigakibart a été bien toléré pendant toute la durée du traitement.
More news about: ERA Congress
Jun 04, 2025, 18:01 ET Congreso ERA: Los datos a largo plazo muestran la eficacia y seguridad sostenidas de zigakibart en pacientes con nefropatía por IgA
profesor Barratt. El tratamiento también condujo a reducciones sostenidas en las inmunoglobulinas séricas, incluida una disminución del 74 % en IgA y Gd-IgA1 patógena, consistente con la inhibición de la vía APRIL. Zigakibart fue bien tolerado en todo momento. La mayoría de los eventos adversos
More news about: ERA Congress
Jun 04, 2025, 18:01 ET ERA Congress：長期データにより、IgA腎症患者におけるzigakibartの長期有効性と安全性が明らかに
結果として、100週めの時点で、タンパク尿はベースラインから60%減少しました。被験者の過半数（55%）が24時間あたり500mg未満、31%が300mg未満となり、より深い寛解を得たことが示されました。推算糸球体濾過量（eGFR）はサブグループ全体で安定を維持しました。Barratt教授は「100週にわたるeGFRの安定化の一貫性は、特にタンパク尿に対する反応を示した群全体において著効しました」と述べました。 治療により、IgAと病原性Gd-IgA1が74%減少するなど、血清免疫グロブリンが持続的に減少しました。これはAPRIL経路阻害と一致しています。 Zigakibartは、全期間を通じて良好に耐容されました。有害事象のほとんどは軽度または中等度であり、治療に関連した重篤な感染症や治療中止は報告されませんでした。最も一般的な有害事象は感染症でしたが、本研究は新型コロナウィルス感染症の最大流行期と重なっていました。
More news about: ERA Congress
Jun 04, 2025, 08:03 ET Omada Launches AI Assistant for Identity Governance Administration
Semantic Kernel, Javi delivers a conversational and user-friendly interface for handling critical IGA tasks. Javi integrates seamlessly with popular collaboration tools such as Microsoft Teams and simplifies IGA management by streamlining processes, such as: Access Request: Submit access requests.
More news about: Omada
Jun 04, 2025, 03:30 ET Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025
Oral presentation Session: FC 14: About C3 and IgA Glomerulonephritis Room: Hall F1 Date:
More news about: Swedish Orphan Biovitrum AB
Jun 04, 2025, 03:03 ET Omada Launches AI Assistant for Identity Governance Administration
Semantic Kernel, Javi delivers a conversational and user-friendly interface for handling critical IGA tasks. Javi integrates seamlessly with popular collaboration tools such as Microsoft Teams and simplifies IGA management by streamlining processes, such as: Access Request: Submit access requests.
More news about: Omada
Jun 03, 2025, 19:15 ET Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction
More news about: Ascletis Pharma Inc.
Jun 03, 2025, 12:00 ET Lumos Launches Albus, The World's First AI Agent for Autonomous Identity Governance
Albus collaborates with IT and security teams automate access policy, reduce risk and bring autonomy to IGA at scale SAN FRANCISCO and NEW YORK, June
More news about: Lumos
May 30, 2025, 16:52 ET Quest Software Announces New $350 Million Capital Infusion to Accelerate AI Innovation and Growth
identity and access management (IAM), privileged access management (PAM), and identity governance administration (IGA). "With AI playing an increasingly vital role in the IAM, PAM, and IGA sectors, our focus remains on delivering cutting-edge solutions that help organizations protect and manage identities
More news about: Quest Software
May 28, 2025, 15:00 ET Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)
galactose-deficient IgA1 (Gd-IgA1) TRAP degrader for the treatment of IgA nephropathy (IgAN) achieved deep, rapid, and sustained reductions in Gd-IgA1. In the Phase 1 study, a single dose of BHV-1400 was subcutaneously administered at a dose of 500 mg and achieved rapid, deep and sustained reductions in Gd-IgA1 of up
More news about: Biohaven Ltd.